Mike Quigley (D-IL)· Introduced April 6, 2026

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

H.R. 8205 · House bill Health

A Democratic bill with 39 Republican cosponsors · See all 103 cosponsors

Last activity November 3, 2026 — Became Public Law No: 119-138.

Became law

Passed both chambers and was signed by the President, or became law without a signature.

Nothing more in Congress: it is law. When it takes effect depends on the dates written into it — some parts start at once, others a year or more later.

Its path through Congress

Introduced
Passed House voice vote
Passed Senate voice vote
To President
Became Law

No one's position on it was recorded: the House by voice vote (members called out yes or no together), and the Senate by voice vote (members called out yes or no together).

What this bill would do

This bill is known as the Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026. It extends the provisions and grants for ALS research found in the original Act through fiscal year 2031. It also makes improvements to the program for grants by requiring the assessment of enrollment, safety, and efficacy data when reviewing grant renewals. Additionally, entities seeking grants must promptly report unexpected new and serious adverse events and safety information to the grant-making institution. Finally, the bill requires the Food and Drug Administration to publish an action plan regarding rare neurodegenerative diseases and a later report describing the actions taken.

Yes

Scored +7
Does this put more money into medical research?
The bill extends the authorization of grants for ALS research through fiscal year 2031.
Scored +6
Would people with disabilities be better off under this?
The bill promotes research into therapies for ALS, a debilitating neurodegenerative disease.
Scored +5
Does this make health care easier to get in general?
The bill extends research grants and enhances FDA oversight to accelerate access to treatments for ALS.